A drug commonly used to treat breast cancer might be able to help people living with hereditary hemorrhagic telangiectasia ...

Presented compelling new preclinical data demonstrating anti-tumor activity for OP-3136, a novel KAT6 inhibitor, with enhanced activity of palazestrant combinations at EORTC-NCI-AACR Symposium on Mole ...

Inhibition of CDK6 may prevent arteriovenous malformations in hereditary hemorrhagic telangiectasia by regulating endothelial ...

Given its novel mechanism of action and proven efficacy ... The CDK4/6 inhibitors palbociclib, ribociclib, and abemaciclib were approved for HR-positive, HER2-negative disease, blocking cyclin ...

and Kisqali (ribociclib), both of which are given alongside hormone therapies. A third new target for breast cancer treatment is the enzyme PARP, which normally acts to help repair damaged genes.

An international team of neuroscientists, led by Duke-NUS Medical School, have uncovered a mechanism that controls the reactivation of neural stem cells, which are crucial for repairing and ...

In response, multiple Feinberg investigators have sought to identify new mechanisms that contribute to glioblastoma tumor growth, which can help tailor the development of new precision medicine ...

This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to recommend ribociclib (Kisqali) as a Category 1 preferred CDK4/6 inhibitor (CDK4/6i) ...

Researchers used drugs Palbociclib and Ribociclib, which are known to block the CDK6 protein in multiplying cancer cells and found that it stopped the abnormal cell growth in animal models with ...